{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:05:30Z","timestamp":1749873930898,"version":"3.41.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We report a case of a patient with metastatic prostate cancer receiving first-line endocrine therapy. Clinical symptoms, PSA level, and CT confirmed the significant progression of his bone metastatic lesions. In comparison to images at baseline, follow-up bone scan incorrectly showed remission of the bone lesions, whereas follow-up <jats:sup>68<\/jats:sup>Ga-DOTA-IBA correctly showed disease progression.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005666","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T15:05:20Z","timestamp":1737731120000},"page":"544-546","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Response Evaluation Using 68Ga-DOTA-IBA in a Case of Metastatic Prostate Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Linwei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"bib1-20250613","doi-asserted-by":"crossref","first-page":"1027792","DOI":"10.3389\/fonc.2022.1027792","article-title":"Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"bib2-20250613","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","article-title":"Safety and efficacy of 68Ga- or 177Lu-labeled DOTA-IBA as a novel theranostic radiopharmaceutical for bone metastases: a phase 0\/I study","volume":"48","author":"Qiu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib3-20250613","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acs.molpharmaceut.2c00978","article-title":"Lutetium177-labeled DOTA-Ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases","volume":"20","author":"Wang","year":"2023","journal-title":"Mol Pharm"},{"key":"bib4-20250613","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-024-01094-6","article-title":"Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases","volume":"14","author":"Li","year":"2024","journal-title":"EJNMMI Res"},{"key":"bib5-20250613","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1148\/radiol.2020192683","article-title":"Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone","volume":"297","author":"Kosmin","year":"2020","journal-title":"Radiology"},{"key":"bib6-20250613","doi-asserted-by":"crossref","first-page":"1364311","DOI":"10.3389\/fonc.2024.1364311","article-title":"Comparison of the relative diagnostic performance of 68Ga-DOTA-IBA and 18F-NaF for the detection of bone metastasis","volume":"14","author":"Deng","year":"2024","journal-title":"Front Oncol"},{"key":"bib7-20250613","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/RLU.0000000000004757","article-title":"Biodistribution and internal dosimetry of 68Ga-DOTA-IBA PET imaging for patients with bone metastases","volume":"48","author":"Yang","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib8-20250613","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.2967\/jnumed.115.169730","article-title":"Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-Fluorocholine PET\/CT","volume":"57","author":"Beheshti","year":"2016","journal-title":"J Nucl Med"},{"key":"bib9-20250613","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1053\/j.semnuclmed.2023.11.005","article-title":"SPECT\/CT, PET\/CT, and PET\/MRI for response assessment of bone metastases","volume":"54","author":"Zamani-Siahkali","year":"2024","journal-title":"Semin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:00:50Z","timestamp":1749816050000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005666","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"2024-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}